See more : RXR Acquisition Corp. (RXRAW) Income Statement Analysis – Financial Results
Complete financial analysis of Emyria Limited (EMD.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Emyria Limited, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- South Shore Holdings Limited (0577.HK) Income Statement Analysis – Financial Results
- Brookfield Office Properties Inc. (BRKFF) Income Statement Analysis – Financial Results
- Minor International Public Company Limited (MINT-R.BK) Income Statement Analysis – Financial Results
- America Great Health (AAGH) Income Statement Analysis – Financial Results
- Decai Decoration CO.,LTD (605287.SS) Income Statement Analysis – Financial Results
Emyria Limited (EMD.AX)
About Emyria Limited
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops cannabinoid-based medicines, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and irritable bowel syndrome; and EMD-RX7 for multiple medical conditions. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.20M | 1.59M | 1.82M | 1.98M | 1.01M | 109.91K | 0.00 |
| Cost of Revenue | 2.37M | 4.91M | 6.24M | 3.56M | 3.80M | 1.73M | 0.00 |
| Gross Profit | -167.55K | -3.32M | -4.41M | -1.58M | -2.79M | -1.62M | 0.00 |
| Gross Profit Ratio | -7.61% | -208.56% | -242.22% | -80.20% | -275.00% | -1,470.68% | 0.00% |
| Research & Development | 2.29M | 1.80M | 2.21M | 2.62M | 1.51M | 221.49K | 0.00 |
| General & Administrative | 3.43M | 3.43M | 4.61M | 1.95M | 2.25M | 477.60K | 184.85K |
| Selling & Marketing | -1.62M | -1.43M | -2.69M | -440.40K | -906.79K | 914.49K | -120.53K |
| SG&A | 1.81M | 2.00M | 1.92M | 1.51M | 1.34M | 869.73K | 64.32K |
| Other Expenses | 0.00 | 2.21M | 1.74M | 1.62M | 427.60K | 0.00 | 0.00 |
| Operating Expenses | 4.10M | 3.80M | 4.12M | 4.13M | 2.84M | 1.09M | 64.32K |
| Cost & Expenses | 6.47M | 8.71M | 10.36M | 7.69M | 6.64M | 2.82M | 64.32K |
| Interest Income | 21.56K | 30.33K | 12.71K | 23.15K | 25.05K | 28.75K | 60.00 |
| Interest Expense | 253.31K | 128.79K | 72.22K | 66.85K | 59.54K | 4.04K | 60.00 |
| Depreciation & Amortization | 694.91K | 400.60K | 390.00K | 344.88K | 383.48K | 94.85K | 257.30K |
| EBITDA | -13.03M | -4.14M | -6.74M | -4.49M | -4.80M | -2.58M | -64.32K |
| EBITDA Ratio | -591.76% | -421.81% | -447.12% | -271.57% | -517.80% | -2,377.22% | 0.00% |
| Operating Income | -4.26M | -7.12M | -8.54M | -5.71M | -5.63M | -2.71M | -64.32K |
| Operating Income Ratio | -193.53% | -446.97% | -468.52% | -289.02% | -555.64% | -2,463.52% | 0.00% |
| Total Other Income/Expenses | -9.72M | -102.99K | 48.51K | 804.61K | 393.10K | 24.70K | 120.51K |
| Income Before Tax | -13.98M | -7.22M | -8.49M | -4.91M | -5.24M | -2.68M | -64.34K |
| Income Before Tax Ratio | -634.81% | -453.44% | -465.86% | -248.30% | -516.85% | -2,441.04% | 0.00% |
| Income Tax Expense | -2.53M | -2.09M | -1.16M | 5.00 | -1.00 | 4.00 | -120.00 |
| Net Income | -11.46M | -5.13M | -7.33M | -4.91M | -5.24M | -2.68M | -64.34K |
| Net Income Ratio | -520.07% | -322.21% | -402.09% | -248.30% | -516.85% | -2,441.04% | 0.00% |
| EPS | -0.03 | -0.02 | -0.03 | -0.02 | -0.03 | -0.01 | 0.00 |
| EPS Diluted | -0.03 | -0.02 | -0.03 | -0.02 | -0.03 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 358.97M | 289.39M | 268.61M | 220.18M | 173.78M | 195.34M | 195.34M |
| Weighted Avg Shares Out (Dil) | 358.97M | 289.39M | 268.61M | 220.18M | 173.78M | 195.34M | 195.34M |
Source: https://incomestatements.info
Category: Stock Reports